Venetoclax Chemotherapy Combo Active in Pediatric AML

The BCL2 inhibitor venetoclax has become a common treatment for some types of leukemias and lymphomas, but use of this agent in pediatric patients is relatively rare. A phase I dose-finding study published in Lancet Oncology evaluated the combination of venetoclax with high-dose cytarabine, with or without idarubicin, in 38 patients aged 3 to 22 years of age with relapsed/refractory acute myeloid leukemia (AML) to determine if this agent is safe and active in a pediatric population.

At a median follow-up of 7.1 months, the objective response rate (ORR) across all doses and schedules evaluated was 69%, including complete response in 46% of patients and complete response with incomplete hematologic recovery in 11% of patients. A dose of 360 mg/m2 of venetoclax (combined with 8 cycles of cytarabine 1000 mg/m2 and an optional single dose of idarubicin 12 mg/m2) was identified as optimal for future study. Among 20 evaluable patients who received this dose, the ORR was 80%, with 70% of patients achieving a complete response with or without complete hematologic recovery.

The adverse events (AEs) were generally consistent with the known safety profiles of venetoclax and high-dose cytarabine. The most common grade 3/4 AEs were febrile neutropenia and infections. One patient died due to treatment-related colitis and sepsis.

The authors concluded that venetoclax plus intensive chemotherapy is safe and active in pediatric patients with relapsed/refractory AML and may represent a treatment alternative for this difficult-to-treat population. The phase II portion of this study is currently ongoing, and studies evaluating venetoclax as a frontline treatment option are planned.

Read more about this article on Lancet Oncology.

Lancet Oncol. Published online March 11, 2020. Full text, Editorial






Clinical Opinion Poll

When would you recommend dabrafenib + trametinib combo for a patient with advanced, symptomatic, PD-L1–low, lung adenocarcinoma and BRAF V600 mutation?